Differing effects of intracortical circuits on plasticity.
Practice of a motor task leads to an increase in amplitude of motor-evoked potentials (MEP) in the exercised muscle. This is termed practice-dependent plasticity, and is abolished by the NMDA antagonist dextromethorphan and the GABA(A) agonist lorazepam. Here, we sought to determine whether specific subtypes of GABA(A) circuits are responsible for this effect by comparing the action of the non-selective agonist, lorazepam with that of the selective GABA(A)-alpha(1) receptor agonist, zolpidem. In seven healthy subjects, transcranial magnetic stimulation (TMS) was used to quantify changes in amplitude of MEP after practice of a ballistic motor task. In addition we measured how the same drugs affected MEP amplitudes and the excitability of a number of cortical inhibitory circuits [short-interval intracortical inhibition (SICI), short-interval afferent inhibition (SAI) and long-interval intracortical inhibition]. This allowed us to explore correlations between drugs effects in measures of cortical excitability and practice-dependent plasticity of MEP amplitudes. As previously reported, lorazepam increased SICI and decreased SAI, while zolpidem only decreased SAI. The new findings were that practice-dependent plasticity of MEPs was impaired by lorazepam but not zolpidem, and that this was negatively correlated with lorazepam-induced changes in SICI but not SAI. This suggests that the intracortical circuits involved in SICI (and not neurons expressing GABA(A)-alpha(1) receptor subunits that are implicated in SAI) may be involved in controlling the amount of practice-dependent MEP plasticity.
Teo
J T H
JT
Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Queen Square, London WC1N 3BG, UK. jteo@ion.ucl.ac.uk
Terranova
C
C
Swayne
O
O
Greenwood
R J
RJ
Rothwell
J C
JC
D000328:Adult; D000704:Analysis of Variance; D018592:Cross-Over Studies; D004311:Double-Blind Method; D019054:Evoked Potentials, Motor / Q000187:drug effects; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology; D058785:GABA-A Receptor Agonists; D006801:Humans; D008140:Lorazepam / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009044:Motor Cortex / Q000187:drug effects / Q000502:physiology*; D009473:Neuronal Plasticity; D011214:Practice, Psychological; D011725:Pyridines / Q000494:pharmacology*; D050781:Transcranial Magnetic Stimulation; D000077334:Zolpidem
D018757:GABA Modulators; D058785:GABA-A Receptor Agonists; D011725:Pyridines; D000077334:Zolpidem; D008140:Lorazepam